CHIEF SCIENTIFIC OFFICER · Enliven Therapeutics, Inc. · Common Stock
Side
A
Value
—
Shares
18.8K
Price
—
Executed
Feb 12, 2026
Disclosed
Feb 17, 2026
Disclosure timeline5 days from execution to publication · legal deadline 2 business days
Feb 12 executedFeb 17, 2026 disclosed
ELVN · daily
Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Grant or award — administrative, little informational value
Relative size+1 / 25
No reported dollar value · new position
Filing timing+6 / 15
Disclosed 3 business days after execution (deadline: 2)
Historical behavior+1 / 15
Routine: 10 prior trades recorded in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Lyssikatos Joseph P filed this Form 4 reporting a grant or award of ELVN on Feb 12, 2026. It became public on Feb 17, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
CHIEF SCIENTIFIC OFFICER
Lyssikatos Joseph Pcik:0001967150
Issuer
Enliven Therapeutics, Inc.cik:0001672619
Revision history · 0
No field has changed since this record was first ingested.
